

#23

Atty. Docket No.: 11111/1210

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Segal	Examiner:	DeCloux
Serial No.:	09/318,870		
Filed:	May 26, 1999	Group Art Unit:	1644
Entitled:	Cytokine Coated Cells and Methods of Modulating an Immune Response to an Antigen	Conf. No.	2018

CERTIFICATE OF FACSIMILE TRANSMISSION
UNDER 37 C.F.R. § 1.6d

I hereby certify that this correspondence and any paper referred to as being enclosed are being facsimile transmitted on the date indicated below to the United States Patent and Trademark Office Fax No. (703) 308-4315

Mathew Beaudet

Name of Person Faxing

Signature of Person Faxing Paper

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Examiner:

In response to the Restriction Requirement dated April 9, 2002, Applicants elect Group I, Claims 1-2, 5-8, 13-14, 17-20, and 22-25 for prosecution on the merits, with traverse. In particular, Applicant submits that Group II (claims 3 and 4) should be included with Group I. Claim 3 depends from claim 1, and claim 4 depends from claim 3. Claim 3 recites "wherein said vaccine composition further comprises an opsonin-enhanced cell" (emphasis added). Thus, claim 3 includes all of the elements of claim 1, and merely adds an additional element. Claim 4, accordingly, includes all the elements of claim 1, and merely recites a specific opsonin. Applicant therefore requests that claims 3 and 4 be included in Group I, and Applicant respectfully requests reconsideration of each of the requirements for restriction.

The Restriction Requirement states that in addition to the election of a particular group, Applicant must further elect a method comprising (1) a specific mammal, (2) a specific cytokine, (3) a specific cell coated with cytokine, (4) a specific cell that is opsonized, (5) a specific


Serial No. 09/318,870

opsonin, (6) a specific ligand, (7) a specific lipid, and (8) a specific receptor. Accordingly, Applicant elects (1) a human, (2) GM-CSF, (3) melanoma cell, (4) melanoma cell, (5) C3B, (6) human GM-CSF, (7) palmitate, (8) human GM-CSF receptor.

Should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 16-0085, Reference No. 11111/1210.

Respectfully submitted,

Date: July 9, 2002

 *Matthew Beaudet*
50,649; signing for

Name: ~~Kathleen M. Williams~~
Registration No.: 34,380
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199
Tel: 617-239-0100